TY - JOUR
T1 - A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings
AU - Ke, Xuehua
AU - Eisenberg Lawrence, Debra F.
AU - Oglesby, Alan
AU - Patel, Jeetvan
AU - Kan, Hong
AU - Boggs, Robert
N1 - Funding Information:
HealthCore Inc. and GlaxoSmithKline plc (GSK) designed and conducted this study, which was funded by GSK. The study sponsor (GSK) contributed to interpretation of the data, and supported the authors in development of the manuscript. GSK is committed to publicly disclosing the results of GSK-sponsored clinical research that evaluates GSK medicines, and as such was involved in the decision to submit. Medical writing and editorial assistance were provided by Clare Slater, PhD, and Louisa Pettinger, PhD, of Fishawack Indicia Ltd, which was funded by GSK. A. Oglesby, H. Kan, R. Boggs and J. Patel were employees of GlaxoSmithKline at the time of the study and own GlaxoSmithKline stock. X. Ke is an employee of HealthCore Inc., which received funding from GlaxoSmithKline to conduct the study. D.F. Eisenberg Lawrence was an employee of HealthCore Inc. at the time of the study. The authors have indicated that they have no other conflicts of interest regarding the content of this article.
Publisher Copyright:
© 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-NC-ND license.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Purpose Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients after regulatory approval of belimumab in the United States. Methods A retrospective, observational study of belimumab users in the HealthCore Integrated Research Database was conducted using administrative claims data (GlaxoSmithKline Clinical Study Register Study ID: 114955). The overall population for analysis was composed of patients who were prescribed belimumab, had ≥6 months pre- and ≥6 months post-index medical and pharmacy eligibility, and at least 1 medical claim for SLE. Patients' clinical and demographic characteristics, treatment history, treatment patterns of belimumab, utilization of other medications, all-cause resource utilization, and costs were assessed. No hypotheses were tested. Findings All patients who were prescribed belimumab had an SLE claim. Patients who met all eligibility criteria (n = 155) were primarily female (94.2%; mean [SD] age, 44 [12] years) and 94.2% had used standard SLE therapies during the pre- and post-index periods. The majority had moderate SLE disease severity pre-index, and there was a small shift (approximately 8%) from moderate to mild SLE after initiation of belimumab. Two thirds of patients remained on belimumab therapy at 6 months post-index. The percentage of patients with any claim for oral corticosteroids remained stable; however, the point estimate for mean daily dose decreased slightly in months 3 to 6 post-index. Inpatient hospital admissions decreased slightly in the post-index period. The point estimate for total costs (excluding belimumab) decreased after initiation of belimumab, although overall total health care costs (including belimumab) increased. Implications All patients with a belimumab prescription had an SLE diagnosis on at least 1 medical claim, and the vast majority of those meeting all eligibility criteria had previously used a standard SLE therapy. Disease severity improved for a number of patients while on belimumab treatment and modest corticosteroid dose reductions were observed in later months. After initiating belimumab, health care costs (excluding belimumab) decreased. GlaxoSmithKline Clinical Study Register Study ID: 114955.
AB - Purpose Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab and standard SLE therapies in patients after regulatory approval of belimumab in the United States. Methods A retrospective, observational study of belimumab users in the HealthCore Integrated Research Database was conducted using administrative claims data (GlaxoSmithKline Clinical Study Register Study ID: 114955). The overall population for analysis was composed of patients who were prescribed belimumab, had ≥6 months pre- and ≥6 months post-index medical and pharmacy eligibility, and at least 1 medical claim for SLE. Patients' clinical and demographic characteristics, treatment history, treatment patterns of belimumab, utilization of other medications, all-cause resource utilization, and costs were assessed. No hypotheses were tested. Findings All patients who were prescribed belimumab had an SLE claim. Patients who met all eligibility criteria (n = 155) were primarily female (94.2%; mean [SD] age, 44 [12] years) and 94.2% had used standard SLE therapies during the pre- and post-index periods. The majority had moderate SLE disease severity pre-index, and there was a small shift (approximately 8%) from moderate to mild SLE after initiation of belimumab. Two thirds of patients remained on belimumab therapy at 6 months post-index. The percentage of patients with any claim for oral corticosteroids remained stable; however, the point estimate for mean daily dose decreased slightly in months 3 to 6 post-index. Inpatient hospital admissions decreased slightly in the post-index period. The point estimate for total costs (excluding belimumab) decreased after initiation of belimumab, although overall total health care costs (including belimumab) increased. Implications All patients with a belimumab prescription had an SLE diagnosis on at least 1 medical claim, and the vast majority of those meeting all eligibility criteria had previously used a standard SLE therapy. Disease severity improved for a number of patients while on belimumab treatment and modest corticosteroid dose reductions were observed in later months. After initiating belimumab, health care costs (excluding belimumab) decreased. GlaxoSmithKline Clinical Study Register Study ID: 114955.
KW - belimumab
KW - real world
KW - systemic lupus erythematosus
KW - utilization patterns
UR - http://www.scopus.com/inward/record.url?scp=84950261216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950261216&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2015.10.008
DO - 10.1016/j.clinthera.2015.10.008
M3 - Article
C2 - 26547483
AN - SCOPUS:84950261216
SN - 0149-2918
VL - 37
SP - 2852
EP - 2863
JO - Clinical therapeutics
JF - Clinical therapeutics
IS - 12
ER -